Corvus Pharma Stock Dips On Bigger-Than-Feared Q4 Loss, But Retail’s Faith Grows Stronger
Research and development expenses in the reported quarter rose by $2 million, primarily due to increased spending on the soquelitinib clinical trial for T-cell lymphoma.
Verint Stock Soars On AI-Fueled Q3 Beat: Retail Sentiment Brightens
Verint highlighted the momentum in AI innovation and customers reporting strong, tangible AI business outcomes with its open platform.